Rehabilitating a brain with Alzheimer's: a proposal
- PMID: 21472092
- PMCID: PMC3066253
- DOI: 10.2147/CIA.S14008
Rehabilitating a brain with Alzheimer's: a proposal
Abstract
Alzheimer's disease (AD) is the most common neurodegenerative disorder, originating sporadically in the population aged over 65 years, and advanced age is the principal risk factor leading to AD development. In spite of the large amount of research going on around the globe and all the information now available about AD, there is still no origin or triggering process known so far. Drugs approved for the treatment of AD include tacrine, donepezil, rivastigmine, galantamine, and memantine. These may delay or slow down the degenerative process for a while, but they can neither stop nor reverse its progression. Because that this might be due to a lack of effect of these drugs on degenerating neurons, even when they are able to potentiate the brain in nondegenerative conditions, we propose here an alternative therapy consisting of initial repair of neuronal membranes followed by conventional drug therapies. The rehabilitation of neurons in a degeneration process would enable the drugs to act more effectively on them and improve the effects of treatment in AD patients.
Keywords: Alzheimer; drugs; rehabilitation.
Figures
Similar articles
-
The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease.Health Technol Assess. 2006 Jan;10(1):iii-iv, ix-xi, 1-160. doi: 10.3310/hta10010. Health Technol Assess. 2006. PMID: 16409879 Review.
-
Current Practices in the Treatment of Alzheimer Disease: Where is the Evidence After the Phase III Trials?Clin Ther. 2015 Aug;37(8):1604-16. doi: 10.1016/j.clinthera.2015.05.510. Epub 2015 Jun 27. Clin Ther. 2015. PMID: 26122885 Review.
-
Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.J Alzheimers Dis. 2014;41(2):615-31. doi: 10.3233/JAD-132690. J Alzheimers Dis. 2014. PMID: 24662102 Review.
-
The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.Health Technol Assess. 2012;16(21):1-470. doi: 10.3310/hta16210. Health Technol Assess. 2012. PMID: 22541366 Free PMC article. Review.
-
The effect of drugs for Alzheimer disease assessed by means of neuroradiological techniques.Curr Med Chem. 2006;13(28):3417-24. doi: 10.2174/092986706779010289. Curr Med Chem. 2006. PMID: 17168714 Review.
Cited by
-
Therapeutic Strategies Aimed at Improving Neuroplasticity in Alzheimer Disease.Pharmaceutics. 2023 Jul 31;15(8):2052. doi: 10.3390/pharmaceutics15082052. Pharmaceutics. 2023. PMID: 37631266 Free PMC article. Review.
-
Natural products as sources of acetylcholinesterase inhibitors: Synthesis, biological activities, and molecular docking studies of osthole-based ester derivatives.Front Plant Sci. 2022 Nov 18;13:1054650. doi: 10.3389/fpls.2022.1054650. eCollection 2022. Front Plant Sci. 2022. PMID: 36466282 Free PMC article.
-
Natural Peptides in Drug Discovery Targeting Acetylcholinesterase.Molecules. 2018 Sep 13;23(9):2344. doi: 10.3390/molecules23092344. Molecules. 2018. PMID: 30217053 Free PMC article. Review.
-
Protective effect of rutin on cognitive impairment caused by phenytoin.Indian J Pharmacol. 2015 Nov-Dec;47(6):627-31. doi: 10.4103/0253-7613.169581. Indian J Pharmacol. 2015. PMID: 26729954 Free PMC article.
References
-
- Perez-Tur J. Genetics and Alzheimer’s disease. Rev Neurol. 2000;30:161–169. - PubMed
-
- Lopez de Munain A. Classification of mitochondrial diseases. Rev Neurol. 1998;26(Suppl 1):S9–S14. - PubMed
-
- Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer’s disease. Trends Pharmacol Sci. 1991;12:383–388. - PubMed
-
- Jarrett JT, Lansbury PTJ. Seeding “one-dimensional crystallization” of amyloid: A pathogenic mechanism in Alzheimer’s disease and scrapie. Cell. 1993;73:1055–1058. - PubMed
-
- Hu X, Hicks CW, He W, et al. BACE1 modulates myelination in the central and peripheral nervous system. Nat Neurosci. 2006;9:1520–1525. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
